Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2

Hui Wang, Yuntao Zhang, Baoying Huang, Wei Deng, Yaru Quan, Wenling Wang, Wenbo Xu, Yuxiu Zhao, Na Li, Jin Zhang, Hongyang Liang, Linlin Bao, Yanfeng Xu, Ling Ding, Weimin Zhou, Hong Gao, Jiangning Liu, Peihua Niu, Li Zhao, Wei Zhen, Hui Fu, Shouzhi Yu, Zhengli Zhang, Guangxue Xu, Changgui Li, Zhiyong Lou, Miao Xu, Chuan Qin, Guizhen Wu, George Fu Gao, Wenjie Tan, Xiaoming Yang, Hui Wang, Yuntao Zhang, Baoying Huang, Wei Deng, Yaru Quan, Wenling Wang, Wenbo Xu, Yuxiu Zhao, Na Li, Jin Zhang, Hongyang Liang, Linlin Bao, Yanfeng Xu, Ling Ding, Weimin Zhou, Hong Gao, Jiangning Liu, Peihua Niu, Li Zhao, Wei Zhen, Hui Fu, Shouzhi Yu, Zhengli Zhang, Guangxue Xu, Changgui Li, Zhiyong Lou, Miao Xu, Chuan Qin, Guizhen Wu, George Fu Gao, Wenjie Tan, Xiaoming Yang

Abstract

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) threatens global public health. The development of a vaccine is urgently needed for the prevention and control of COVID-19. Here, we report the pilot-scale production of an inactivated SARS-CoV-2 vaccine candidate (BBIBP-CorV) that induces high levels of neutralizing antibodies titers in mice, rats, guinea pigs, rabbits, and nonhuman primates (cynomolgus monkeys and rhesus macaques) to provide protection against SARS-CoV-2. Two-dose immunizations using 2 μg/dose of BBIBP-CorV provided highly efficient protection against SARS-CoV-2 intratracheal challenge in rhesus macaques, without detectable antibody-dependent enhancement of infection. In addition, BBIBP-CorV exhibits efficient productivity and good genetic stability for vaccine manufacture. These results support the further evaluation of BBIBP-CorV in a clinical trial.

Keywords: BBIBP-CorV; SARS-CoV-2; inactivated vaccine.

Conflict of interest statement

Declaration of Interests The authors declare no competing interests.

Copyright © 2020 Elsevier Inc. All rights reserved.

Figures

Graphical abstract
Graphical abstract
Figure S1
Figure S1
SARS-CoV-2 Maximum Likelihood Phylogenetic Tree Related to Figure 1 The SARS-CoV-2 isolates used in this study are indicated with black arrows and labeled. Viral strains were isolated from infected patients who traveled from the indicated continent/area.
Figure 1
Figure 1
Characterization of the SARS-CoV-2 Vaccine Candidate BBIBP-CorV (A) Viral titers of three strains of different generations. (B) Flowchart of BBIBP-CorV preparation. (C) Culture conditions. The left panel shows the effect of cell culture time on BBIBP-CorV stock virus titer, the middle panel shows the growth kinetics of the Vero cells for BBIBP-CorV stock culture, and the right panel shows the effect of inoculation MOI on BBIBP-CorV stock virus titer. (D) Inactivation kinetics of three batches of virus supernatant. (E) The protein composition of BBIBP-CorV were evaluated by incubating with antibodies targeting N protein (left panel) and S protein (middle panel) and incubation with convalescent patient sera (right panel). h, harvest; c, concentrated viral solution; p, purified viral solution. (F) Representative electron micrograph of BBIBP-CorV. Scale bar: 100 nm.
Figure S2
Figure S2
Neutralization of SARS-CoV-2 Strains HB02, CQ01, and QD01 by the Sera of Mice Vaccinated with BBIBP-CorV, Related to Figure 1 Mice were intraperitoneally injected with 8 μg/does of BBIBP-CorV at one time, and the ability of their sera to neutralize three SARS-CoV-2 strains was tested (n = 5) day 14 day after inoculation.
Figure S3
Figure S3
Serum Biochemical Parameters in Rhesus Macaques after Vaccination and Challenge with Living Virus, Related to Figure 3 Rhesus macaques were intramuscularly immunized twice on days 0 and 14, and live virus challenge was conducted on day 24 (the dotted line). Blood was collected, and serum biochemical parameters were monitored at different time points. Glu (glucose), T-Bil (total bilirubin), ALT (alanine aminotransferase), AST (aspartate aminotransferase), ALP (alkaline phosphatase), γ-GT (γ-glutamyl transpeptidase), TP (total protein), Alb (albumin), TG (triglycerides), TC (total cholesterol), CREA (creatinine), UA (uric acid), UREA (blood urea), CK (creatine kinase), LDH (lactate dehydrogenase). The data are presented as the mean ± SD. ∗p < 0.05 and ∗∗∗p < 0.001 versus the placebo group (n = 2 in the placebo group, n = 4 in the 2 μg/dose and 8 μg/dose groups). The dotted line on the y axis indicates the normal upper and lower lines of the data.
Figure 2
Figure 2
BBIBP-CorV Immunization Elicits a Neutralizing Antibody Response in Different Animals with Different Doses and Immunization Programs (A) Mouse neutralization antibody (NAb) levels with one-dose (D0) immunization. Mice were injected intraperitoneally with high (8 μg/dose), middle (4 μg/dose), or low (2 μg/dose) doses of vaccine, and the NAb levels at 7 days, 14 days, 21 days, and 28 days after the first immunization were tested by the microtitration method (n = 10). (B) NAb levels with different immunization interval programs via two-dose immunization. Mice were injected intraperitoneally by using two-time immunization (D0/D7; D0/D14; D0/D21), and the NAb levels at 7 days after the second immunization were tested by the microtitration method (n = 10). (C) Mouse neutralization antibody levels with three-dose (D0/D7/D14) immunization. Mice were inoculated intraperitoneally with high (8 μg/dose), middle (4 μg/dose), or low (2 μg/dose) doses of vaccine at 0, 7, and 14 days, and NAb levels at 7, 14, 21, and 28 days after the first immunization were tested by the microtitration method (n = 10). (D) Mouse NAb levels with different immunization programs. Mice were injected intraperitoneally with high (8 μg/dose), middle (4 μg/dose), or low (2 μg/dose) doses of vaccine by using one-dose (D0), two-dose (D0/D21), and three-dose (D0/D7/D14) immunization programs, respectively, and the NAb levels at 28 days after the first immunization were checked by the microtitration method (n = 10). (E) Rabbits (n = 5), guinea pigs (n = 10), rats (n = 10), and mice (n = 10) were immunized with high (8 μg/dose), middle (4 μg/dose), or low (2 μg/dose) doses of vaccine by one-dose (D0) immunization, and the NAb levels at 21 days after the first immunization were tested by the microtitration method. (F) Cynomolgus monkeys (n = 10), rabbits (n = 5), guinea pigs (n = 10), rats (n = 10), and mice (n = 10) were immunized with high (8 μg/does), middle (4 μg/dose), and low (2 μg/dose) doses of vaccine by three-dose (D0/D7/D14) immunization, and the NAb levels at 21 days after the first immunization were tested by the microtitration method. For (A–F), error bars reflect the geometric SD.
Figure 3
Figure 3
Immunogenicity and Protective Efficacy of BBIBP-CorV in Nonhuman Primates (A) Experimental strategy. (B) Macaques were immunized twice with 2 μg/dose (n = 4) or 8 μg/dose (n = 4) of BBIBP-CorV or placebo (n = 2). The NAb titers were measured. Data are presented as geometric mean with geometric SD. (C–G) The protective efficacy of BBIBP-CorV against SARS-CoV-2 challenge at 10 days after second immunization was evaluated in macaques. Changes in clinical signs (temperature, C) were recorded. Viral loads in throat (D) and anal (E) swabs obtained from macaques at 3, 5, and 7 days post inoculation. (F) Viral loads in all seven lung lobes collected from all macaques at day 7 post inoculation were determined by real-time PCR. All data are presented as mean ± SEM from four independent experiments for the BBIBP-CorV groups and two independent experiments for the placebo group; error bars reflect the SEM. Data points represent the individual macaques. Asterisks indicate significance: ∗∗p < 0.01. Dotted lines indicate the limit of detection. (G) Histopathological changes in lungs of macaques at day 7 post inoculation. All macaques received vaccination showed normal lung with focal mild interstitial pneumonia in few lobes. Scale bars are indicated in the panels.
Figure S4
Figure S4
Individual Data for Temperature, Viral Load, and Body Weight of Animals in Efficacy and Safety Evaluation, Related to Figures 3C–3E Individual (A) temperature, viral load in (B) throat and (C) anal swab data in nonhuman primate efficacy evaluation. Individual body weight of (D) rats (n = 5) and (E) cynomolgus monkeys (n = 10) in safety evaluation (Related to Figures 4A and 4C).
Figure 4
Figure 4
Safety Evaluation of BBIBP-CorV in Rats, Guinea Pigs, and Nonhuman Primates (A) Body weight analysis of rats in the experimental group and control group (n = 5). Male and female rat weight mean are used in this plot. Plot with individual data is presented in Figure S4D. (B) Body weight analysis of guinea pigs in the experimental groups (0.1 × dose/guinea pig, 1 × dose/guinea pig) and negative control and positive control groups (n = 9). (C) Cynomolgus monkeys were intramuscularly injected four times on days 1, 8, 15, and 22 with low (2 μg/dose), middle (4 μg/dose), and high (8 μg/dose) doses of BBIBP-CorV or placebo. Body weight analysis of cynomolgus monkeys (n = 10) in all four groups. Male and female cynomolgus monkey weight mean are used in this plot. Plot with individual data is presented in Figure S4E. (D) Hematological analysis of cynomolgus monkey in all four groups (n = 10). The percentages of the lymphocyte subsets CD3+, CD3+CD4+ (labeled CD4+), CD3+CD8+ (labeled CD8+), CD20+, and CD3+CD4+/CD3+CD8+ (labeled CD4+/CD8+) were monitored at day −1 (1 day before vaccination), day 25 (3 days after the third vaccination), and day 36 (14 days after the fourth vaccination). (E) The key cytokines TNF-α, IFN-γ, IL-2, IL-4, IL-5, and IL-6 were examined at days −1, 1 (the day for the first vaccination), 4, 15, 22, 25, and 36, respectively. For (A–E), values are shown as the mean ± SD

References

    1. Chan J.F., Yuan S., Kok K.H., To K.K., Chu H., Yang J., Xing F., Liu J., Yip C.C., Poon R.W. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395:514–523.
    1. Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y., Qiu Y., Wang J., Liu Y., Wei Y. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–513.
    1. Gao Q., Bao L., Mao H., Wang L., Xu K., Yang M., Li Y., Zhu L., Wang N., Lv Z. Rapid development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020 doi: 10.1126/science.abc1932.
    1. Gary E.N., Weiner D.B. DNA vaccines: prime time is now. Curr. Opin. Immunol. 2020;65:21–27.
    1. Katoh K., Misawa K., Kuma K., Miyata T. MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform. Nucleic Acids Res. 2002;30:3059–3066.
    1. Li Q., Guan X., Wu P., Wang X., Zhou L., Tong Y., Ren R., Leung K.S.M., Lau E.H.Y., Wong J.Y. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N. Engl. J. Med. 2020;382:1199–1207.
    1. Lu R., Zhao X., Li J., Niu P., Yang B., Wu H., Wang W., Song H., Huang B., Zhu N. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565–574.
    1. Lurie N., Saville M., Hatchett R., Halton J. Developing Covid-19 Vaccines at Pandemic Speed. N Engl J Med. 2020;382:1969–1973.
    1. Munster V.J., Feldmann F., Williamson B.N., van Doremalen N., Pérez-Pérez L., Schulz J., Meade-White K., Okumura A., Callison J., Brumbaugh B. Respiratory disease in rhesus macaques inoculated with SARS-CoV-2. Nature. 2020 doi: 10.1038/s41586-020-2324-7.
    1. Price M.N., Dehal P.S., Arkin A.P. FastTree 2--approximately maximum-likelihood trees for large alignments. PLoS ONE. 2010;5:e9490.
    1. Ramakrishnan M.A. Determination of 50% endpoint titer using a simple formula. World J. Virol. 2016;5:85–86.
    1. Shan C., Yao Y.-F., Yang X.-L., Zhou Y.-W., Wu J., Gao G., Peng Y., Yang L., Hu W., Xiong J. Infection with Novel Coronavirus (SARS-CoV-2) Causes Pneumonia in the Rhesus Macaques. Research Square. 2020 doi: 10.21203/rs.2.25200/v1.
    1. Stern P.L. Key steps in vaccine development. Annals of Allergy, Asthma & Immunology. 2020 doi: 10.1016/j.anai.2020.01.025.
    1. Tan W.J., Zhao X., Ma X.J., Wang W.L., Niu P.H., Xu W.B., Gao G.F., Wu G. A novel coronavirus genome identified in a cluster of pneumonia cases—Wuhan, China 2019−2020. China CDC Weekly. 2020;2:61–62.
    1. van Doremalen N., Lambe T., Spencer A., Belij-Rammerstorfer S., Purushotham J.N., Port J.R., Avanzato V., Bushmaker T., Flaxman A., Ulaszewska M. ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques. bioRxiv. 2020 doi: 10.1101/2020.05.13.093195.
    1. Wang Q., Zhang L., Kuwahara K., Li L., Liu Z., Li T., Zhu H., Liu J., Xu Y., Xie J. Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates. ACS Infect. Dis. 2016;2:361–376.
    1. Wang C., Horby P.W., Hayden F.G., Gao G.F. A novel coronavirus outbreak of global health concern. Lancet. 2020;395:470–473.
    1. Yang Z.Y., Werner H.C., Kong W.P., Leung K., Traggiai E., Lanzavecchia A., Nabel G.J. Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. Proc. Natl. Acad. Sci. USA. 2005;102:797–801.
    1. Yu G., Smith D.K., Zhu H., Guan Y., Lam T.T. ggtree: an r package for visualization and annotation of phylogenetic trees with their covariates and other associated data. Methods Ecol. Evol. 2017;8:28–36.
    1. Yu J., Tostanoski L.H., Peter L., Mercado N.B., McMahan K., Mahrokhian S.H., Nkolola J.P., Liu J., Li Z., Chandrashekar A. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science. 2020 doi: 10.1126/science.abc6284.
    1. Yu P., Qi F., Xu Y., Li F., Liu P., Liu J., Bao L., Deng W., Gao H., Xiang Z. Age-related rhesus macaque models of COVID-19. Animal Model Exp Med. 2020;3:93–97.
    1. Zhang C., Zhou D. Adenoviral vector-based strategies against infectious disease and cancer. Hum. Vaccin. Immunother. 2016;12:2064–2074.
    1. Zhou P., Yang X.L., Wang X.G., Hu B., Zhang L., Zhang W., Si H.R., Zhu Y., Li B., Huang C.L. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–273.
    1. Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., Zhao X., Huang B., Shi W., Lu R., China Novel Coronavirus Investigating and Research Team A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J. Med. 2020;382:727–733.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel